NASHVILLE, Tenn., September 15, 2022--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings ("Revance" or the "Company"), today announced the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 1,200,000 additional shares, at a price to the public of $25.00 per share. All of the shares were offered by Revance. The aggregate gross proceeds from the public offering were $230.0 million, before deducting underwriting discounts and commissions and other offering expenses.
Goldman Sachs & Co. LLC, Cowen and Company, LLC and Guggenheim Securities, LLC acted as joint book-running managers for the offering. Barclays Capital Inc. also acted as a bookrunner for the offering.
The securities described above were offered by Revance pursuant to an automatic shelf registration statement on Form S-3 (File No. 333-250998) previously filed with the Securities and Exchange Commission (the "SEC") on November 27, 2020. A final prospectus supplement and accompanying prospectus relating to the public offering were filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may also be obtained by contacting Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526, or by email at Prospectusemail@example.com; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by telephone at (833) 297-2926, or by email at PostSaleManualRequests@broadridge.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017, or by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (888) 603-5847, or by email at firstname.lastname@example.org.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Revance is a commercial stage biotechnology company focused on developing and commercializing innovative aesthetic and therapeutic offerings, including DAXXIFY™ (DaxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers, and OPUL®, a relational commerce platform for aesthetic practices. Revance has also partnered with Viatris Inc. to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance’s therapeutics pipeline is currently focused on muscle movement disorders including evaluating DaxibotulinumtoxinA for Injection in cervical dystonia and upper limb spasticity.
Revance, the Revance logo and OPUL® are registered trademarks of Revance Therapeutics, Inc.
Resilient Hyaluronic Acid® and RHA® are registered trademarks of Teoxane SA.
BOTOX® is a registered trademark of Allergan, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915006062/en/
Revance Therapeutics, Inc.:
Sara J. Fahy